Trial Profile
A single-centre, single-dose, randomized, open-label, three-period crossover study to evaluate the effects of food on the pharmacokinetics of ponatinib in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Squamous cell cancer; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors ARIAD Pharmaceuticals
- 08 Dec 2015 New trial record